These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35407612)

  • 1. Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature.
    Wlazło M; Kierkuś J
    J Clin Med; 2022 Apr; 11(7):. PubMed ID: 35407612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
    Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
    Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
    Yerushalmy-Feler A; Olbjorn C; Kolho KL; Aloi M; Musto F; Martin-de-Carpi J; Lozano-Ruf A; Yogev D; Matar M; Scarallo L; Bramuzzo M; de Ridder L; Kang B; Norden C; Wilson DC; Tzivinikos C; Turner D; Cohen S
    Inflamm Bowel Dis; 2024 Feb; 30(2):159-166. PubMed ID: 37042978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study.
    Wlazło M; Meglicka M; Wiernicka A; Osiecki M; Kierkuś J
    Children (Basel); 2022 Dec; 10(1):. PubMed ID: 36670562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.
    Olbjørn C; Rove JB; Jahnsen J
    Paediatr Drugs; 2020 Aug; 22(4):409-416. PubMed ID: 32378002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P
    United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
    Ribaldone DG; Pellicano R; Vernero M; Caviglia GP; Saracco GM; Morino M; Astegiano M
    Scand J Gastroenterol; 2019 Apr; 54(4):407-413. PubMed ID: 30945576
    [No Abstract]   [Full Text] [Related]  

  • 9. Biologic drugs for inflammatory bowel disease.
    Yanai S; Matsumoto T
    Nihon Rinsho; 2017 Mar; 75(3):403-407. PubMed ID: 30566782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Ahmed W; Galati J; Kumar A; Christos PJ; Longman R; Lukin DJ; Scherl E; Battat R
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e361-e379. PubMed ID: 33798711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients.
    Mas EB; Calvo XC
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature.
    Gold SL; Steinlauf AF
    Gastroenterol Hepatol (N Y); 2021 Sep; 17(9):406-414. PubMed ID: 34602905
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.
    Gisbert JP; Chaparro M
    Drugs; 2020 Jul; 80(11):1085-1100. PubMed ID: 32562207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease.
    Yamamoto-Furusho JK; Bosques-Padilla FJ; Martínez-Vázquez MA;
    Rev Gastroenterol Mex (Engl Ed); 2021; 86(1):70-85. PubMed ID: 33317930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
    Conrad MA; Kelsen JR
    Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there an optimal sequence of biologic therapies for inflammatory bowel disease?
    Bressler B
    Therap Adv Gastroenterol; 2023; 16():17562848231159452. PubMed ID: 37057077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the development of new biologics in inflammatory bowel disease.
    Ungar B; Kopylov U
    Ann Gastroenterol; 2016; 29(3):243-8. PubMed ID: 27366024
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.